Row:Sales $ 	39,807 $ 	39,498 $ 	42,237
Row:Costs, Expenses and Other
			Row:Materials and production 	13,891 	14,934 	16,768
Row:Marketing and administrative 	9,762 	10,313 	11,606
Row:Research and development 	10,124 	6,704 	7,180
Row:Restructuring costs 	651 	619 	1,013
Row:Other (income) expense, net 	720 	1,527 	(11,613)
Row:	35,148 	34,097 	24,954
Row:Income Before Taxes 	4,659 	5,401 	17,283
Row:Taxes on Income 	718 	942 	5,349
Row:Net Income 	3,941 	4,459 	11,934
Row:Less: Net Income Attributable to Noncontrolling Interests 	21 	17 	14
Row:Net Income Attributable to Merck & Co., Inc. $ 	3,920 $ 	4,442 $ 	11,920
Row:Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders $ 	1.42 $ 	1.58 $ 	4.12
Row:Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders $ 	1.41 $ 	1.56 $ 	4.07
Row:Consolidated Statement of Comprehensive Income
			Row:Net Income Attributable to Merck & Co., Inc. 	$ 3,920 $ 4,442 $ 11,920
Row:Other Comprehensive Income (Loss) Net of Taxes:
	Row:Net unrealized (loss) gain on derivatives, net of reclassifications 	(66) (126) 398
Row:Net unrealized (loss) gain on investments, net of reclassifications 	(44) (70) 57
Row:Benefit plan net (loss) gain and prior service (cost) credit, net of amortization 	(799) 579 (2,077)
Row:Cumulative translation adjustment 	(169) (208) (504)
Row:	(1,078) 175 (2,126)
Row:Comprehensive Income Attributable to Merck & Co., Inc. 	$ 2,842 $ 4,617 $ 9,794
Row:	2016 	2015
Row:Assets
		Row:Current Assets
Cash and cash equivalents $ 	6,515 	$ 8,524
Row:Short-term investments Accounts receivable (net of allowance for doubtful accounts of $195 in 2016
and $165 in 2015) (excludes accounts receivable of $10 in 2015
classified in Other assets) 	7,826 7,018 	4,903
6,484
Row:Inventories (excludes inventories of $1,117 in 2016 and $1,569
in 2015 classified in Other assets - see Note 6) 	4,866 	4,700
Row:Other current assets 	4,389 	5,140
Row:Total current assets 	30,614 	29,751
Row:Investments 	11,416 	13,039
Row:Property, Plant and Equipment (at cost)
		Row:Land 	412 	490
Row:Buildings 	11,439 	12,154
Row:Machinery, equipment and office furnishings 	14,053 	14,261
Row:Construction in progress 	1,871 	1,525
Row:	27,775 	28,430
Row:Less: accumulated depreciation 	15,749 	15,923
Row:	12,026 	12,507
Row:Goodwill 	18,162 	17,723
Row:Other Intangibles, Net 	17,305 	22,602
Row:Other Assets 	5,854 	6,055
Row:$ 	95,377 	$ 101,677
Row:Liabilities and Equity
		Row:Current Liabilities
Loans payable and current portion of long-term debt $ 	568 	$ 2,583
Row:Trade accounts payable 	2,807 	2,533
Row:Accrued and other current liabilities 	10,274 	11,216
Row:Income taxes payable 	2,239 	1,560
Row:Dividends payable 	1,316 	1,309
Row:Total current liabilities 	17,204 	19,201
Row:Long-Term Debt 	24,274 	23,829
Row:Deferred Income Taxes 	5,077 	6,535
Row:Other Noncurrent Liabilities Merck & Co., Inc. Stockholders’ Equity
Common stock, $0.50 par value
	8,514 	7,345
Row:Authorized - 6,500,000,000 shares
Issued - 3,577,103,522 shares in 2016 and 2015 	1,788 	1,788
Row:Cash Flows from Operating Activities
	Row:Net income
$ 	3,941 $ 4,459 $ 11,934
Row:Adjustments to reconcile net income to net cash provided by operating activities:
	Row:Depreciation and amortization
	5,441 6,375 6,691
Row:Intangible asset impairment charges
	3,948 162 1,222
Row:Charge related to the settlement of worldwide Keytruda patent litigation
	625 — —
Row:Foreign currency devaluation related to Venezuela
	— 876 —
Row:Net charge related to the settlement of Vioxx shareholder class action litigation
	— 680 —
Row:Gain on divestiture of Merck Consumer Care business
	— — (11,209)
Row:Gain on AstraZeneca option exercise
	— — (741)
Row:Loss on extinguishment of debt
	— — 628
Row:Equity income from affiliates
	(86) (205) (257)
Row:Dividends and distributions from equity method affiliates 	16 50 185
Row:Deferred income taxes
	(1,521) (764) (2,600)
Row:Share-based compensation 	300 299 278
Row:Other
	313 874 34
Row:Net changes in assets and liabilities:
	Row:Accounts receivable
	(619) (480) (554)
Row:Inventories 	206 805 79
Row:Trade accounts payable
	278 (37) 593
Row:Accrued and other current liabilities 	(2,018) (8) 1,635
Row:Income taxes payable
	124 (266) (21)
Row:Noncurrent liabilities 	(809) (277) 190
Row:Other
	237 (5) (98)
Row:Net Cash Provided by Operating Activities
	10,376 12,538 7,989
Row:Cash Flows from Investing Activities
	Row:Capital expenditures
Purchases of securities and other investments
	(1,614) (1,283) (1,317)
(15,651) (16,681) (24,944)
Row:Noncurrent liabilities 	(809) 	(277) 	190
Row:Other
	237 	(5) 	(98)
Row:Net Cash Provided by Operating Activities
	10,376 	12,538 	7,989
Row:Cash Flows from Investing Activities
			Row:Capital expenditures
	(1,614) 	(1,283) 	(1,317)
Row:Purchases of securities and other investments
	(15,651) 	(16,681) 	(24,944)
Row:Proceeds from sales of securities and other investments
	14,353 	20,413 	15,114
Row:Divestiture of Merck Consumer Care business, net of cash divested
	— 	— 	13,951
Row:Dispositions of other businesses, net of cash divested
	— 	316 	1,169
Row:Proceeds from AstraZeneca option exercise
	— 	— 	419
Row:Acquisition of Cubist Pharmaceuticals, Inc., net of cash acquired
	— 	(7,598) 	—
Row:Acquisition of Idenix Pharmaceuticals, Inc., net of cash acquired
	— 	— 	(3,700)
Row:Acquisitions of other businesses, net of cash acquired 	(780) 	(146) 	(181)
Row:Acquisition of Bayer AG collaboration rights
	— 	— 	(1,000)
Row:Cash inflows from net investment hedges 	29 	139 	195
Row:Other
	453 	82 	(80)
Row:Net Cash Used in Investing Activities
	(3,210) 	(4,758) 	(374)
Row:Cash Flows from Financing Activities
			Row:Net change in short-term borrowings
	— 	(1,540) 	(460)
Row:Payments on debt 	(2,386) 	(2,906) 	(6,617)
Row:Proceeds from issuance of debt
	1,079 	7,938 	3,146
Row:Purchases of treasury stock 	(3,434) 	(4,186) 	(7,703)
Row:Dividends paid to stockholders
	(5,124) 	(5,117) 	(5,170)
Row:Other dividends paid
	— 	— 	(77)
Row:Proceeds from exercise of stock options
	939 	485 	1,560
Row:Other
	(118) 	(61) 	79
Row:Net Cash Used in Financing Activities 	(9,044) 	(5,387) 	(15,242)
